Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Guardant Health announced plans to sell stock and raise $400 million in new cash. Guardant burned through nearly $300 million over the past year, so the new fund raise should cover about 16 months of cash burn.

Why Guardant Health Stock Just Crashed 10%

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will ring the opening bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, August 28, 2024. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after w.

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average

Revenue increased by 29% year over year, reaching $177.2 million. Net loss widened to $102.6 million due to unrealized losses in equity investments.

Guardant Health Q2 Losses Rise Amid Revenue Growth

Guardant Health, Inc. (NASDAQ:GH ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Jack Meehan - Nephron Research Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Patrick Donnelly - Citigroup Tycho Peterson - Jefferies Operator Good afternoon. Thank you for attending today's Guardant Health Q2 2024 Earnings Call.

Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $177.2 million for the second quarter of 2024, an increase of 29% over the second quarter of 2023 Reported 49,400 tests to clinical customers and 10,475 tests to biopharmaceutical customers in the second quarter of 2024, representing increases of 14% and 56%, respect.

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish results today from the COSMOS study confirming the high sensitivity and specificity of the Guardant Reveal blood test in predicting recurrence of colorectal cancer (CRC). The COSMOS (COnquer Solid Malignancies by blOod Screening) study is the largest study to date evaluating.

Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield™ blood test, recently approved by the U.S. Food and Drug Administration (FDA), is now covered by Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary colorectal cancer (CRC) screening. The Centers for Medicare & Medicaid Services (CMS) now covers the Shield test based on the criteria established in its Na.

Guardant Health's FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the acceptance of its health outcomes study, the CAN-SCREEN model, for publication in the Journal of Medical Economics, highlighting the importance of combining clinically meaningful screening performance with high patient adherence in colorectal cancer (CRC) screening to optimize CRC-related health outcomes. The CAN-SCREEN model addresses the significant limitations of.

Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies

Guardant Health Inc.'s stock rose 2.4% Monday, after the company said the Food and Drug Administration has approved its blood test for colon-cancer screening in adults 45 and older who are at average risk for the disease.

Guardant Health's stock up after FDA approves its blood test for colon-cancer screening

Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.

Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test

On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.

FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption

Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to boost the rate of screenings for the disease as fewer eligible Americans opt for colonoscopies.

Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers

The U.S. Food and Drug Administration on Monday approved Guardant Health's blood test to detect a cancer that starts in the colon or rectum.

US FDA approves Guardant Health's blood-based cancer test

PALO ALTO, Calif.--(BUSINESS WIRE)--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.

Guardant Health's Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a major upgrade to its market-leading Guardant360 liquid biopsy test. The new enhanced test evaluates biomarkers in 739 genes in total, which is 10 times more cancer biomarkers than the previous version of Guardant360 evaluated. The test can also identify an extensive array of emerging biomarkers to precisely characterize cancer and can quantify disease burd.

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

Adaptive Biotechnologies

Illumina

Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.

3 Precision Medicine Stocks Tailoring Treatments

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in a.

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Adaptimmune Therapeutics

Viking Therapeutics

For most of the year, biotech has been one of the most explosive sectors on the market. Far from over, further upside is likely, thanks to some of the top biotech stocks with catalysts.

3 Biotech Moonshots With Imminent Catalyst Potential

Exact Sciences

The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.

News for Guardant Health Inc Stock (GH)